The FDA has approved ensitrelvir (Xocova – Shionogi), a SARS-CoV-2 main protease inhibitor, for postexposure prophylaxis of COVID-19 in patients ≥12 years old who had contact with an infected individual. Ensitrelvir is the first oral antiviral drug to be approved in the US for this indication. The parenteral monoclonal antibody combinations bamlanivimab and etesevimab and casirivimab and imdevimab (REGEN-COV) are no longer authorized for postexposure prophylaxis of COVID-19 in the US.
PHARMACOLOGY — Ensitrelvir inhibits SARS-CoV-2...
ISSUE
The FDA has approved Omlonti (Ocuvex), a 0.002% ophthalmic solution of the prostaglandin EP2 receptor agonist omidenepag isopropyl, for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Omidenepag is the first selective prostaglandin EP2 receptor agonist to be approved in the US. It has been available in Japan since 2018.
STANDARD TREATMENT — Glaucoma is a progressive optic neuropathy associated with increased IOP (normal range 8-22 mm Hg), which is the only disease-related factor that can be modified.
Topical prostaglandin analogs (PGAs) are the drugs of choice for initial treatment of primary open-angle glaucoma. They increase uveoscleral outflow and, to a lesser extent, outflow through the trabecular meshwork. Dosed once daily, usually at night, they typically lower IOP by 25-30%. PGAs are generally …